Literature DB >> 29593476

Novel and Recurrent Mutations in the FGFR3 Gene and Double Heterozygosity Cases in a Cohort of Brazilian Patients with Skeletal Dysplasia.

Maria E S Gomes1, Thatiane Y Kanazawa2, Fernanda R Riba1, Natálya G Pereira3, Maria C C Zuma1, Natana C Rabelo1, Maria T Sanseverino4, Dafne D G Horovitz3, Juan C Llerena3,5,6, Denise P Cavalcanti2, Sayonara Gonzalez1.   

Abstract

Mutations in the fibroblast growth factor receptor 3 gene (FGFR3) cause achondroplasia (ACH), hypochondroplasia (HCH), and thanatophoric dysplasia types I and II (TDI/TDII). In this study, we performed a genetic study of 123 Brazilian patients with these phenotypes. Mutation hotspots of the FGFR3 gene were PCR amplified and sequenced. All cases had recurrent mutations related to ACH, HCH, TDI or TDII, except for 2 patients. One of them had a classical TDI phenotype but a typical ACH mutation (c.1138G>A) in combination with a novel c.1130T>C mutation predicted as being pathogenic. The presence of the second c.1130T>C mutation likely explained the more severe phenotype. Another atypical patient presented with a compound phenotype that resulted from a combination of ACH and X-linked spondyloepiphyseal dysplasia tarda (OMIM 313400). Next-generation sequencing of this patient's DNA showed double heterozygosity for a typical de novo ACH c.1138G>A mutation and a maternally inherited TRAPPC2 c.6del mutation. All mutations were confirmed by Sanger sequencing. A pilot study using high-resolution melting (HRM) technique was also performed to confirm several mutations identified through sequencing. We concluded that for recurrent FGFR3 mutations, HRM can be used as a faster, reliable, and less expensive genotyping test than Sanger sequencing.

Entities:  

Keywords:  Achondroplasia; Double heterozygosity; FGFR3; High-resolution melting; Hypochondroplasia; Thanatophoric dysplasia

Year:  2018        PMID: 29593476      PMCID: PMC5836216          DOI: 10.1159/000486697

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  18 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Clinical epidemiology of skeletal dysplasias in South America.

Authors:  Cecília O Barbosa-Buck; Iêda M Orioli; Maria da Graça Dutra; Jorge Lopez-Camelo; Eduardo E Castilla; Denise P Cavalcanti
Journal:  Am J Med Genet A       Date:  2012-03-09       Impact factor: 2.802

Review 3.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

4.  ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility.

Authors:  T D Otto; E A Vasconcellos; L H F Gomes; A S Moreira; W M Degrave; L Mendonça-Lima; M Alves-Ferreira
Journal:  Genet Mol Res       Date:  2008-09-23

5.  Failed PCR amplifications of MBP-STR alleles due to polymorphism in the primer annealing region.

Authors:  L Gusmão; A Amorim; M J Prata; L Pereira; M V Lareu; A Carracedo
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

6.  Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis.

Authors:  Xiang He; Feng Xie; Zhao-rui Ren
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-17

7.  Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome.

Authors:  D J Wilkin; J K Szabo; R Cameron; S Henderson; G A Bellus; M L Mack; I Kaitila; J Loughlin; A Munnich; B Sykes; J Bonaventure; C A Francomano
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

Review 8.  Anticancer molecules targeting fibroblast growth factor receptors.

Authors:  Guang Liang; Zhiguo Liu; Jianzhang Wu; Yuepiao Cai; Xiaokun Li
Journal:  Trends Pharmacol Sci       Date:  2012-08-09       Impact factor: 14.819

9.  Achondroplasia is defined by recurrent G380R mutations of FGFR3.

Authors:  G A Bellus; T W Hefferon; R I Ortiz de Luna; J T Hecht; W A Horton; M Machado; I Kaitila; I McIntosh; C A Francomano
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

10.  A gene for achondroplasia-hypochondroplasia maps to chromosome 4p.

Authors:  M Le Merrer; F Rousseau; L Legeai-Mallet; J C Landais; A Pelet; J Bonaventure; M Sanak; J Weissenbach; C Stoll; A Munnich
Journal:  Nat Genet       Date:  1994-03       Impact factor: 38.330

View more
  5 in total

1.  [Preparation of GH/tPA double transgenic mice and gene expression analysis].

Authors:  S Song; D Li; Z He; T Zhang; Y Cheng; M Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

Review 2.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

3.  A novel deletion variant in TRAPPC2 causes spondyloepiphyseal dysplasia tarda in a five-generation Chinese family.

Authors:  Cai Zhang; Caiqi Du; Juan Ye; Feng Ye; Renfa Wang; Xiaoping Luo; Yan Liang
Journal:  BMC Med Genet       Date:  2020-05-29       Impact factor: 2.103

Review 4.  FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.

Authors:  Alec Kacew; Randy F Sweis
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

Review 5.  Identification of a novel mutation of FGFR3 gene in a large Chinese pedigree with hypochondroplasia by next-generation sequencing: A case report and brief literature review.

Authors:  Guixiang Yao; Guangxin Wang; Dawei Wang; Guohai Su
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.